Mumbai, September 9 (Kiran News) — Shares of Morepen Laboratories advanced over 3 percent on Tuesday after its subsidiary, Morepen Medipath, executed a joint venture (JV) agreement with Bimedical FZE.
The proposed JV company will engage in the manufacturing, trading, and sale of medical device-related products. As part of the agreement, Morepen Medipath will acquire a 50 percent stake in the new company. Through this investment, Morepen Laboratories will indirectly hold 30 percent of the JV’s shareholding.
On the BSE, Morepen Laboratories was trading at ₹50.97, up by ₹1.87 or 3.81 percent from its previous close of ₹49.10. The stock opened at ₹49.62 and hit an intraday high of ₹51.93 and a low of ₹49.62. A total of 4,76,914 shares were traded during the day.
The Group ‘A’ stock, with a face value of ₹2, has a 52-week high of ₹100.80 (September 10, 2024) and a 52-week low of ₹41.66 (April 7, 2025). Over the last week, it has moved between ₹48.37 and ₹51.93.
Morepen Laboratories’ current market capitalization stands at ₹2,802.78 crore. Promoters hold 35.65 percent of the company’s equity, while institutional investors own 3.24 percent and non-institutional shareholders hold 61.11 percent.
The company is engaged in the manufacturing and sale of APIs (bulk drugs), home diagnostics, formulations, and OTC products, and continues to expand its presence in the healthcare segment through strategic ventures.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.